Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Jul;28(1):37–44. doi: 10.1111/j.1365-2125.1989.tb03503.x

Comparison of Sawchuk-Zaske and Bayesian forecasting for aminoglycosides in seriously ill patients.

C P Denaro 1, P J Ravenscroft 1
PMCID: PMC1379968  PMID: 2775614

Abstract

1. Individual pharmacokinetic parameters and predicted steady-state serum concentrations of aminoglycosides were calculated by Sawchuck-Zaske (SZ) and Bayesian methods. 2. Predicted concentrations were compared with observed steady-state concentrations for 36 seriously ill patients with systemic infections. Four aminoglycoside concentrations were used for the SZ method. Differing numbers of serum aminoglycoside samples were used in the Bayesian parameter estimation: one sample Bayesian used one post-infusion concentration, two sample Bayesian used a trough plus one post-infusion concentrations and four sample Bayesian used a trough plus three post-infusion concentrations. 3. 79% of the SZ predictions were with +/- 2 mg l-1 of the observed peak concentrations, and 72% of the two sample Bayesian predictions were within the same range. 82% of SZ and the two sample Bayesian predictions were within +/- 1 mg l-1 of the observed trough concentrations. 4. A confidence interval comparison of estimated pharmacokinetic parameters and precision for the predicted concentrations showed no important differences between the SZ and the two sample Bayesian. The four sample Bayesian was the most precise method. 5. We conclude that the Bayesian forecasting method utilizing a trough plus one post-infusion concentrations is as useful as the SZ method which requires three to four serum concentrations in individualizing aminoglycoside therapy for seriously ill patients.

Full text

PDF
37

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barza M., Brown R. B., Shen D., Gibaldi M., Weinstein L. Predictability of blood levels of gentamicin in man. J Infect Dis. 1975 Aug;132(2):165–174. doi: 10.1093/infdis/132.2.165. [DOI] [PubMed] [Google Scholar]
  2. Burton M. E., Brater D. C., Chen P. S., Day R. B., Huber P. J., Vasko M. R. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther. 1985 Mar;37(3):349–357. doi: 10.1038/clpt.1985.51. [DOI] [PubMed] [Google Scholar]
  3. Burton M. E., Chow M. S., Platt D. R., Day R. B., Brater D. C., Vasko M. R. Accuracy of Bayesian and Sawchuk-Zaske dosing methods for gentamicin. Clin Pharm. 1986 Feb;5(2):143–149. [PubMed] [Google Scholar]
  4. Chan R. A., Benner E. J., Hoeprich P. D. Gentamicin therapy in renal failure: a nomogram for dosage. Ann Intern Med. 1972 May;76(5):773–778. doi: 10.7326/0003-4819-76-5-773. [DOI] [PubMed] [Google Scholar]
  5. Denaro C. P., Ravenscroft P. J. Usefulness of estimating individual pharmacokinetic data for aminoglycoside therapy in seriously ill patients. Aust N Z J Med. 1987 Oct;17(5):526–532. doi: 10.1111/j.1445-5994.1987.tb00114.x. [DOI] [PubMed] [Google Scholar]
  6. Gill M. A., Kern J. W. Altered gentamicin distribution in ascitic patients. Am J Hosp Pharm. 1979 Dec;36(12):1704–1706. [PubMed] [Google Scholar]
  7. Hull J. H., Sarubbi F. A., Jr Gentamicin serum concentrations: pharmacokinetic predictions. Ann Intern Med. 1976 Aug;85(2):183–189. doi: 10.7326/0003-4819-85-2-183. [DOI] [PubMed] [Google Scholar]
  8. Iliadis A., Bachir-Raho M., Bruno R., Favre R. Bayesian estimation and prediction of clearance in high-dose methotrexate infusions. J Pharmacokinet Biopharm. 1985 Feb;13(1):101–115. doi: 10.1007/BF01073659. [DOI] [PubMed] [Google Scholar]
  9. Jackson G. G., Riff L. J. Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis. 1971 Dec;124 (Suppl):S185–S191. doi: 10.1093/infdis/124.supplement_1.s185. [DOI] [PubMed] [Google Scholar]
  10. Jolley M. E., Stroupe S. D., Wang C. H., Panas H. N., Keegan C. L., Schmidt R. L., Schwenzer K. S. Fluorescence polarization immunoassay. I. Monitoring aminoglycoside antibiotics in serum and plasma. Clin Chem. 1981 Jul;27(7):1190–1197. [PubMed] [Google Scholar]
  11. Lacarelle B., Granthil C., Manelli J. C., Bruder N., Francois G., Cano J. P. Evaluation of a Bayesian method of amikacin dosing in intensive care unit patients with normal or impaired renal function. Ther Drug Monit. 1987 Jun;9(2):154–160. doi: 10.1097/00007691-198706000-00005. [DOI] [PubMed] [Google Scholar]
  12. Lesar T. S., Rotschafer J. C., Strand L. M., Solem L. D., Zaske D. E. Gentamicin dosing errors with four commonly used nomograms. JAMA. 1982 Sep 10;248(10):1190–1193. [PubMed] [Google Scholar]
  13. Moore R. D., Smith C. R., Lietman P. S. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984 Oct;77(4):657–662. doi: 10.1016/0002-9343(84)90358-9. [DOI] [PubMed] [Google Scholar]
  14. Moore R. D., Smith C. R., Lietman P. S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984 Mar;149(3):443–448. doi: 10.1093/infdis/149.3.443. [DOI] [PubMed] [Google Scholar]
  15. Noone P., Parsons T. M., Pattison J. R., Slack R. C., Garfield-Davies D., Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974 Mar 16;1(5906):477–481. doi: 10.1136/bmj.1.5906.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pennington J. E., Dale D. C., Reynolds H. Y., MacLowry J. D. Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever. J Infect Dis. 1975 Sep;132(3):270–275. doi: 10.1093/infdis/132.3.270. [DOI] [PubMed] [Google Scholar]
  17. Platt D. R., Matthews S. J., Sevka M. J., Comer J. B., Quintiliani R., Cunha B. A., Nightingale C. H., Chow M. S. Comparison of four methods of predicting serum gentamicin concentrations in adult patients with impaired renal function. Clin Pharm. 1982 Jul-Aug;1(4):361–365. [PubMed] [Google Scholar]
  18. Sawchuk R. J., Zaske D. E., Cipolle R. J., Wargin W. A., Strate R. G. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther. 1977 Mar;21(3):362–369. doi: 10.1002/cpt1977213362. [DOI] [PubMed] [Google Scholar]
  19. Sawchuk R. J., Zaske D. E. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976 Apr;4(2):183–195. doi: 10.1007/BF01086153. [DOI] [PubMed] [Google Scholar]
  20. Sheiner L. B., Beal S. L. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci. 1982 Dec;71(12):1344–1348. doi: 10.1002/jps.2600711209. [DOI] [PubMed] [Google Scholar]
  21. Sheiner L. B., Beal S. L. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981 Aug;9(4):503–512. doi: 10.1007/BF01060893. [DOI] [PubMed] [Google Scholar]
  22. Sheiner L. B., Beal S., Rosenberg B., Marathe V. V. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979 Sep;26(3):294–305. doi: 10.1002/cpt1979263294. [DOI] [PubMed] [Google Scholar]
  23. Sheiner L. B., Halkin H., Peck C., Rosenberg B., Melmon K. L. Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentrations. Ann Intern Med. 1975 May;82(5):619–627. doi: 10.7326/0003-4819-82-5-619. [DOI] [PubMed] [Google Scholar]
  24. Sheiner L. B., Rosenberg B., Melmon K. L. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972 Oct;5(5):411–459. doi: 10.1016/0010-4809(72)90051-1. [DOI] [PubMed] [Google Scholar]
  25. Siber G. R., Echeverria P., Smith A. L., Paisley J. W., Smith D. H. Pharmacokinetics of gentamicin in children and adults. J Infect Dis. 1975 Dec;132(6):637–651. doi: 10.1093/infdis/132.6.637. [DOI] [PubMed] [Google Scholar]
  26. Vozeh S., Muir K. T., Sheiner L. B., Follath F. Predicting individual phenytoin dosage. J Pharmacokinet Biopharm. 1981 Apr;9(2):131–146. doi: 10.1007/BF01068078. [DOI] [PubMed] [Google Scholar]
  27. Wenk M., Vozeh S., Follath F. Serum level monitoring of antibacterial drugs. A review. Clin Pharmacokinet. 1984 Nov-Dec;9(6):475–492. doi: 10.2165/00003088-198409060-00001. [DOI] [PubMed] [Google Scholar]
  28. Zaske D. E., Bootman J. L., Solem L. B., Strate R. G. Increased burn patient survival with individualized dosages of gentamicin. Surgery. 1982 Feb;91(2):142–149. [PubMed] [Google Scholar]
  29. Zaske D. E., Cipolle R. J., Rotschafer J. C., Solem L. D., Mosier N. R., Strate R. G. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations. Antimicrob Agents Chemother. 1982 Mar;21(3):407–411. doi: 10.1128/aac.21.3.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Zaske D. E., Sawchuk R. J., Gerding D. N., Strate R. G. Increased dosage requirements of gentamicin in burn patients. J Trauma. 1976 Oct;16(10):824–828. doi: 10.1097/00005373-197610000-00014. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES